"Precision Medicine Moves From Promise To Reality"
Most people think of illness in a binary way: a patient is either sick or well. But scientists have found a more nuanced reality. “Looking beneath the data in medical records, at health information across millions of patients, we have found a large spectrum of disease and disease risk that can inform individualized treatment plans in a more sophisticated and tailored way than the ‘one size fits all’ paradigm of today,” said Eric Schadt, the founder and CEO of Sema4, a patient-centered predictive health company. Over the past few years, the Mount Sinai Health System has created several entities to advance the growing field of precision medicine, including the Institute for Next Generation Healthcare and its Lab100, a hybrid clinic and research lab, and Schadt’s own Sema4, when was spun out from Mount Sinai in 2017. The future of health care will depend on harnessing genetic and personalized information, and it is already improving the wellbeing of many.
- Eric E. Schadt, PhD, Dean, Precision Medicine, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, Founder and CEO, Sema4
- Alan B. Copperman, MD, Clinical Professor, Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai, Director, Division of Reproductive Endocrinology and Infertility, Vice Chairman, Department of Obstetrics, Gynecology and Reproductive Science, Mount Sinai Health System
- Samir Parekh, MBBS, Associate Professor, Oncological Sciences, Medicine, Hematology and Medical Oncology, Director, Translational Research in Myeloma, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
- Joel Dudley, PhD, Director, Institute for Next Generation Healthcare, Associate Professor, Genetics and Genomic Sciences, Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, Executive Vice President, Precision Health, Mount Sinai Health System
- Adam Margolin, PhD, Senior Associate Dean, Precision Medicine, Icahn School of Medicine at Mount Sinai
- Judy H. Cho, MD, Director, Institute for Personalized Medicine, Professor, Genetics and Genomic Sciences, Medicine, Gastroenterology, Icahn School of Medicine at Mount Sinai
Diabetes May Accelerate Blood Cancer Growth, Yet Survival Outcomes Differ by Race
Sep 29, 2023 View All Press ReleasesResearchers Find Treatment Options for Patients Whose Blood Cancer Relapses After CAR-T
Nov 04, 2022 View All Press ReleasesPotentially Serious Side Effect Seen in Patient after Immunotherapy
Dec 10, 2021 View All Press Releases